# Cyclica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyclica

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.cyclicarx.com
- Total disclosed funding: $20M
- Latest round: Series B (Jun 23, 2020)
- Investors on record: 7

## About

Cyclica Inc., based in Toronto, Canada, is a biotechnology company dedicated to leveraging artificial intelligence for drug discovery and development, enhancing the efficiency of biopharmaceutical processes.Cyclica Inc. operates in the biotechnology sector, focusing on AI-driven drug discovery. Founded in 2013 in Toronto, Canada, by Jason Mitakidis, the company has successfully completed a total of 8 deals. Its most recent deal occurred on May 8, 2023, when Recursion Pharmaceuticals, Inc. led an ADD-ON funding round, raising USD 40.000 mn. This latest round has brought the total amount raised by Cyclica to USD 23.000 mn.Cyclica specializes in providing innovative solutions through its products designed for the biotechnology sector. Its core offerings enhance operational efficiency and improve customer engagement by focusing on drug discovery and development. The company caters primarily to organizations in the healthcare industry, offering products that integrate seamlessly with existing systems to maximize productivity and provide real-time data analytics. Its clientele includes a range of enterprises across North America, Europe, and Asia, addressing needs in drug development and operational challenges through its refined product offerings.Cyclica's revenue model is based on a combination of subscription-based services and direct sales to various sectors within the biotechnology industry. Services typically involve annual or monthly subscriptions for its software solutions, with pricing tiers reflecting the features offered. The company also partners with distributors to enhance product delivery to end-users in retail and wholesale sectors. This structured approach emphasizes long-term client relationships, resulting in consistent revenue through recurring streams.Cyclica plans to utilize the USD 40.000 mn raised in May 2023 to support its strategy centered around advancing artificial intelligence in biotechnology. The company aims to develop new products and enhance its existing offerings, with several innovations in the pipeline. Additionally, it is targeting expansion into key markets in Europe and Asia to increase its global footprint. With funding from Recursion Pharmaceuticals, Inc., Cyclica is positioned to accelerate its growth initiatives and enhance its contribution to the biotechnology industry.

## Funding rounds

- Series B, Jun 23, 2020, $17M — CHIESI Farmaceutici S.p.A., Drive Capital, GreenSky Ventures
- Series A, Jul 26, 2017, $1.8M — Epic Capital Management, GreenSky Ventures, Hanhai Studio, Uni-Innovation Group
- Series A, Sep 22, 2016, $1.8M — GreenSky Ventures, China Canada Angel Alliance
- Seed, Aug 15, 2015 — GreenSky Ventures

## Investors

- GreenSky Ventures (https://capitalatlas.ai/funds/greensky-ventures) — Seed, Series A, Series B
- China Canada Angel Alliance — Series A
- Epic Capital Management — Series A
- Hanhai Studio (https://capitalatlas.ai/funds/hanhai-studio) — Series A
- Uni-Innovation Group (https://capitalatlas.ai/funds/uni-innovation-group) — Series A
- CHIESI Farmaceutici S.p.A. — Series B
- Drive Capital (https://capitalatlas.ai/funds/drive-capital) — Series B